LIVEdrugglpeli-lilly

FDA approves Retatrutide this year?

$0.6M Vol··3 commenti·Closes Dec 31, 2026

Storia probabilità YES / NO

Yes13%

No88%

Regole

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food an…

Statistiche live

Volume 24h

$180

Volume totale

$569.8k

Liquidity

$1.3k

Commenti